HERG Screening Market Forecasts to 2028 – Global Analysis By Type (Gene KCNH2, Mutant KCNH2 and Other Types), Ion Channel (Voltage Gated, Ligand Gated and Other Ion Channels), Application (Antiarrhythmic, Antipsychotic, Antibiotics and Other Applications)

HERG Screening Market Forecasts to 2028 – Global Analysis By Type (Gene KCNH2, Mutant KCNH2 and Other Types), Ion Channel (Voltage Gated, Ligand Gated and Other Ion Channels), Application (Antiarrhythmic, Antipsychotic, Antibiotics and Other Applications) and By Geography

According to Stratistics MRC, the Global HERG Screening Market is accounted for $1942.10 million in 2022 and is expected to reach $4756.25 million by 2028 growing at a CAGR of 16.10% during the forecast period. The human Ether-a-go-go-Related Gene, also known as HERG, is a gene that produces the Kvll protein. 1 the potassium ion channel's alpha subunit. By giving the cardiac action potential a repolarizing current, its channels assist in controlling the heartbeat. The HERG evaluations are now before the submission of the investigational new drug, this was one of the prerequisites set by the regulatory agencies. Some HERG screening assays resemble patch clamp assays that are either manual or automatic. Microelectrode array, fluorescence polarization analysis and HERG radioligand binding test. Auto-patching clamp check the HERG current at different concentrations.

According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018.

Market Dynamics

Driver

Increase in heart disease prevalence

In the entire world, heart disease is the leading cause of death for both men and women. An American will have a myocardial infarction every 40 seconds, according to the American College of Cardiology. The article continued by noting that emergency medical services estimated that 356,461 Americans had gone into cardiac arrest outside of a hospital in 2017, and emergency medical services treatment had begun in 52% of those cases. Only 18.7% of the patients initially had a heart rhythm that could be shockable by an AED, such as ventricular fibrillation or ventricular tachycardia. Adults had an overall survival rate of 10.4% and an 8.4% good functional status.

Restraint

Expensive herg screening products

The global HERG Screening market expected to hinder growth during the forecast period. The cost of the vial used in HERG screening is high as a result of the market's poor growth. Utilizing modern technology has resulted in an increase in the price of the products used in the screening process. For USD 879 per vial, the Eurofins DiscoverX Corporation offers a precision recombinant HERG potassium ion channel membrane preparation. These factors are expected to restrict market growth.

Opportunity

Unexploited markets

Companies that manufacture products or partner with smaller companies operating in new markets as distributors additionally, markets in China, India, Brazil, Russia, and South Africa remain untapped. In these nations, heart disease is also becoming more prevalent. A study that was released in 2016 found that there were 23.8 million people in India who had ischemic heart disease. 1,6.5 million stroke cases were reported in India in 2016. The increased prevalence of these untapped markets means that businesses have a lot of room to grow.

Threat

Drug toxicity of herg

The global HERG Screening market expected to hamper growth during the forecast period. The human ether-a-go-go-related gene (hERG) potassium ion channel is frequently unintentionally blocked by drug candidates. Long QT syndrome (LQTS), a serious, life-threatening cardiac side effect, is caused by the blockage. Therefore, by eliminating toxic drug candidates, a virtual screening method to predict drug-induced hERG-related cardiotoxicity could speed up drug discovery. One of the adverse effects and a significant contributor to drug withdrawals during drug discovery is cardiac toxicity.

Covid-19 Impact

In the early stages of the COVID-19 pandemic, there were no specialized diagnostic tests available to identify the illness in patients. Initially, alternative diagnostic procedures were used, but they weren't very successful. Due to the unavailability of certain COVID-19 diagnostic tests, diagnostic manufacturers had lucrative opportunities to release COVID-19 diagnostic kits. Utilizing this chance, a number of established companies as well as a few start-ups from different nations introduced COVID-19 diagnostic kits into the local as well as international markets.

The voltage gated segment is expected to be the largest during the forecast period

During the forecasted period, voltage-gated ion channels held the largest share in the hERG market. Screening for the human ether-a-go-go-related gene (hERG) in the early stages of drug discovery and development, robust growth in pharmaceutical companies for hERG screening of lead compounds, and difficulties in developing products useful for pharmaceutical and biotechnology applications are the main factors attributed to the market growth of this segment.

The gene kcnh2 segment is expected to have the highest CAGR during the forecast period

The Gene KCNH2 segment is anticipated to grow at a rate of 15.20% over the course of the forecast period. This channel is particularly important for both the generation and transmission of electrical impulses because it is in charge of removing positively charged potassium atoms from the cells. This is because it is in charge of moving the atoms of potassium. The synthesis of potassium channels is regulated by the KCNH2 gene, which also provides the necessary instructions for doing so. The eventual emergence of cardiac arrhythmias is primarily caused by the KCNH2 mutation. Similar to the KCNH2 gene, a mutation or KCNH2 deficiency can result in prolonged QT syndrome. Prolonged QT syndrome is thought to affect one in 5,000 to one in 10,000 individuals worldwide, according to estimates.

Region with largest share

The North America region market is estimated to witness a largest share of the global HERG Screening market during the forecast period. An American citizen will experience a myocardial infarction every 40 seconds, according to the study of the American College of Cardiology. 356,460 Americans went through an out-of-hospital cardiac arrest in 2017, and emergency medical services were called in for 52% of those cases, the report claims. Only 18.75% of the initially reported cardiac rhythms were ventricular fibrillation, ventricular tachycardia, or shockable by an AED. 8.4% of adults who were hospitalized survived to be released, and 10.4% of them had good functional status.

Region with highest CAGR

Asia Pacific is projected to have the highest CAGR over the forecast period. During the forecast period, Asia-Pacific is anticipated to have the highest CAGR. This region has more new product launches, which will increase the amount of R&D in the herg screening market. Additionally, the Asia-Pacific region receives more approvals for new drugs, which will spur market expansion. In this region, there will likely be an increase in demand for drug formulation and development to treat illnesses and disorders as a result of the rising number of approvals.

Key players in the market

Some of the key players in HERG Screening market include A PerkinElmer Company, Abcam PLC, ABR-Affinity BioReagents, Inc., AstraZeneca Plc, Aureus Sciences, Aurora Biomed Inc., AVIVA Biosciences, B'SYS GmbH, Cambridge Bioscience Ltd, Cellular Dynamics International, ChanTest Corporation, Charles River Laboratories Inc., ChemAxon, Creative bioarray, Cyprotex Limited, Eurofins-Cerep SA., Merck KGaA, Metrion biosciences and Molecular Devices LLC.

Key Developments

In March 2020, Charles River Laboratories entered a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service. In addition to Charles River being the exclusive contract research organization distributing the Patholytix preclinical solution to clients, the organizations will work together to co-develop deep learning-enabled tools to support accelerated pathology analytics.

In July 2017, Eurofins Scientific announced the acquisition of Discover X, a leader in drug discovery products and services across all stages of discovery from target identification and lead discovery to preclinical and beyond.

Types Covered
• Gene KCNH2
• Mutant KCNH2
• Other Types

Ion Channels Covered
• Voltage Gated
• Ligand Gated
• Other Ion Channels

Applications Covered
• Antiarrhythmic
• Antipsychotic
• Antibiotics
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities,Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements